NSCLC Harboring NRG1 Fusion clinical trials at UC Health
1 research study open to eligible people

• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  open to eligible people ages 18 years and up

  This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.

  at UC Irvine

Last updated: October 21, 2019